Saw this post from the IHub board. It's a good

New Post Public Reply Private Reply Replies (1) Message Board
kickazzstocktrader
5,619
Saw this post from the IHub board. It's a good read

ViaDerma = $$'s coming this year! Here's all the DD you need to know.

March 8, 2017
~ Sales, labeling & marketing being launched!! Industry expert hired!! ~
http://www.marketwired.com/press-release/viad...201662.htm

~Ivan Klarich Reviews~
https://www.linkedin.com/in/ivanklarich/
Aidan Roark Makepeace
Founder/CEO at WRKPRTY
Aidan Roark worked with Ivan in different groups
I have had the privilege of working with and for Ivan on several software development and business strategy projects ranging from the start-up to the enterprise level and can say, without reservation, Ivan is amazing to work with. Ivan is a thoughtful and inspiring leader and team-builder, and an energetic, diligent, and reliable visionary in strategic planning and operations/executive management. I welcome every opportunity to work with Ivan and can wholeheartedly recommend his services, as well as those of his extensive team of associates.
Mireille Buiel
HR Lead at FindHotel
Mireille worked with Ivan but at different companies
I have worked together with Ivan as consultants at a California based FMCG manufacturing company. I got to know him as a value-based strategic thinker that keeps his eye on the long-term goal. He is able to bring teams and entrepreneurs quickly to the ‘pain points’ and find new practical solutions for their business (model) issues. I would definitely recommend him for complex organizational and commercial challenges.
John Fanaris
Co-Owner/GM/Sommelier at Rustic Kitchen
John worked with Ivan but at different companies
Preparing for growth and putting the right pieces together are crucial to success and Ivan brings the tools needed to the table. He has a non-confrontational demeanor in his analysis of your internal methodology with the uncanny knack of straight forward communication and a tell-it-like-it-is constructive advice. He is an expert at analyzing company operations and culture to develop a comprehensive strategy to reach your goals. If you are looking to take your company to the next level, Ivan is your man.
Jackie Lapin / Authors, Speakers, Get Leads, Get Booked
?? AUTHORS & SPEAKERS, GET LEADS, GET BOOKED–Book Your Own Speaking Engagements at Transformational Venues & Events
Jackie Lapin / worked with Ivan but at different companies
Ivan is one of the most brilliant forward-thinking business visionaries I've ever encountered. That skill is anchored by real world practical strategic analytics and implementation that ensures success. I want him on my team whenever I'm launching something new, improve what's already working or need to fix something that's not!

http://www.hopedance.org/home/awakenings/2920...happy-life


February 15, 2017
~ Additional patents are being filed in the MMJ space! ~
http://www.marketwired.com/press-release/viad...196107.htm

http://www.thedailychronic.net/2017/68842/cli...diabetics/
http://www.thedailychronic.net/2017/69698/stu...f-opioids/


February 8, 2017
~ CEO speaking at the Global Diabetic Foot Conference in Houston March 21-23, 2017 ~
http://www.marketwired.com/press-release/dr-c...194656.htm

https://www.drugs.com/otc/676986/viabecline.html
https://www.linkedin.com/pulse/healing-diabet...ve-pozek-1


February 3, 2017
~ MASSIVE sales coming.. 500,000 units x $125 = $62,500,000 in 2017~
http://www.marketwired.com/press-release/viad...193323.htm


January 11, 2017
~Filed a patent application with the USPTO for its proprietary innovative transdermal delivery system~
http://www.marketwired.com/press-release/viad...187878.htm


November 30, 2016
"Patent Pending Transdermal System" can deliver medications and nutrients into the body through the skin. The solution combined with FDA registered drugs can increase the absorption as much as 100 times directly to the localized treatment areas,
http://www.marketwired.com/press-release/viad...179850.htm


November 14, 2016
Filed Patent Pending use of its innovative transdermal system for the delivery of (CBD's) Calanoids and (THC) Tetrahydrocannabinol for the treatment of several diseases
http://www.marketwired.com/press-release/viad...175498.htm


Current Market Cap ~ $9.5mill, March 10, 2017~

Share Structure
Authorized Shares 400,000,000 a/o Mar 07, 2017
Outstanding Shares 321,232,603 a/o Mar 07, 2017
-Restricted 57,975,478 a/o Mar 07, 2017
-Unrestricted 263,257,125 a/o Mar 07, 2017
Held at DTC 246,331,609 a/o Mar 07, 2017
Float 222,337,825 a/o Jan 25, 2017


2dollarbill ~ REPOST
just doing my part here...

Lead Product TetraStem
World’s strongest broad spectrum tetracycline-based topical antibiotic with proven results. Used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries.
Very low water content and optimum (low) viscosity. Uses both a chemical AND physical kill mechanism which is advantageous over traditional antibiotics which use only a chemical kill mechanism and has a better resistance profile.

Potential Markets
ViaDerma is developing products in many fields of use, including:
Topical antibiotics- $6 billion/year
Toenail antifungal drugs- $3 billion/year
Diabetic amputations- $3 billion/year
Global acne- $3.02 billion/year
Psoriasis- $7.3 billion/year
Eczema- $2.5 billion/year

Other potential markets include burns, anti-aging/wrinkle remover cream, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. Innovative, patent pending dual carrier transdermal technology which can transform oral medication into topical products. Ability to enable active ingredients with a rapid transport direct to the site of action.

Ability to be used in any field including Sports Nutrition Supplements, Cosmetics, First Aid Products, Wound Care, and Skin Diseases like Acne, Eczema, and Psoriasis. Dual carrier liquid which can possess life enhancing technology with up to four year shelf-life. Facilitates transfer of chemicals through the stratum corneum with a diffusion constant 10,000x higher. Strong Advanced Biological Coverage (ABC) which has higher concentrations, faster penetration and is more effective than conventional antibiotics. ABC produces desirable results in ~24 hours or less compared to 5-7 days. It kills all harmful gram-positive and gram-negative bacteria that have been available for testing.

1- back in 2.25.2014 philips manufactured there last fda approval of tetrastem, its a 3 year shelf life as im able to see
2 - in 5.28.2014 VDRM started to manufacture there first fda approval of tetrastem, same 3 year shelf life
3 - now heres where it make huge sense in 3.2014 VDRM gets the rights to manufacture tetrastem from phlips....1 month after they start there first manufacture of tetrastem
4 - the 3 - 6 - 9 month studies kick in in a huge way, and now VDRM as of 1.2017 manufactures 500,000 bottles for sale,
...basically they took what worked expanded on it and said this is huger than we thought
5 - 12.2016 VDRM files for uopdated Viabecline patent - which is purely application - so that means anyone, anywhere, anytime they use tetrastem - pure play on licensing application
6 - back in 2015 rumors started that both PFE and MRK and Endo pharma were looking at VDRM
7 - 2.2017 Dr Otiko to write a paper on diabetic ulcers showing massive results - which means all roads to viabecline

articles of interest ( get them off the web )
1 - from a 2.2011 study reposted in 1.2017 paraplegic uses tetrastem with stem cells and walks again ( philips put the article out )
2 - 3.2015 onychmycosis article
3 - 11.2016 viabecline article
4 - 12.2016 diabetic ulcers study vdrm issued
5 - 12.2016 viabecline patent applied for
6 - 1.2017 vdrm 500,000 bottles manufactured for 2017 grossing 62-65M in sales

viabecline is a delivery of tetrastem - which can take any oral as well and apply to ointment application

PFE is all about viagra, now imagine a lotion for f on f , not just a pill, and youve opened a huge market in the world away of same sex...mrk is all about diabetes and with application wise they want in too, add in JNJ which bandaids work and graduate to a 1000% increase in healing and they want in too...

VDRM product is 85% cheaper and works better - Viabecline is what the entire game is all about here - application technology

PFE Viagra is a category killer but it is a pill - and a pill is a introduction internally to the blood stream which out of fear a great portion of the population will just not take, now factor in a female Viagra alternative that is topical and replace the male Viagra with the same topical and its obvious that PFE will be forced to enter some sort of licensing agreement to hold onto there market share and as well look to capitalize on the female market as well ( m on f , and f on f ) there are those that will only use topical not internal

MRK, LLY and MNKD are the diabetic market and its huge - toenail fungal market - now add on a turnaround solution they have been needing for years, to treat at home foot infections ( home care largest market globally ) and that market alone is extraordinary with multiple companies all vying to be the dominant player and VDRM having the solution to license

JNJ marketplace is wounds - the band , now graduate it to the ability to speed the process up say 10 fold to heal any scrapes scratched wounds and to hold there market-share JNJ will be forced to enter some sort of licensing deal just to hold the line or risk crippling there empire quite easily

MRK and JNJ baldness market is in a level all itself, as its a do it yourself world we live in - add a just for men/ ladies crowd solution to expand into the baldness market and make that a CVS Walgreen's etc play for direct access more licensing

without even touching on the other markets there is exceptional growth here

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


~Info on Dr. Chris Otiko, CEO of ViaDerma~

Radio interview from December 9, 2016.
https://upticknewswire.com/viaderma-ceo-dr-ch...ic-wounds/
https://www.linkedin.com/in/chris-ayo-otiko-80284b5/
https://www.linkedin.com/pulse/healing-diabet...otic-otiko
https://www.barbadostoday.bb/2014/07/05/mirac...diabetics/
http://www.neurogenx.com/testimonial/christop...-director/
https://www.ratemds.com/doctor-ratings/233443...da-CA.html



~Patent/Licensing/Manufacturing Info~
https://www.drugs.com/otc/129916/tetrastem.html
(licensed as Diabecline and Viabecline). Regardless of who owns or has the rights to the patent, ViaDerma has licensing rights, and has filed a new patent pending application for the transdermal system as per January 11, 2017 PR




GLTA

LONG $VDRM

ViaDerma, Inc. (VDRM) Stock Research Links

VDRM Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

FirstEnergy's Timely Transformer Boosts Lakewood Power

Updated Category News Views 149

Lakewood's Power Strengthened Ahead of Schedule Nothing like beating your own deadlines to put a spring in your step, huh? FirstEnergy (NYSE:FE) has pulled off just that by energizing a second big ol’ transformer in Lakewood ahead of time. Feels like a solid win under their belts, especially in a world where delays seem to be the norm. Now, this isn't just any swap-out...

Continue Reading
Exploring 'Deeper Prayer': A Journey with Apostle Paul

Updated Category News Views 15

A Deep Dive into the Prayers of Apostle Paul Gary P. Rohrmayer's latest devotional takes believers on a unique journey, exploring the Apostle Paul's prayers across his missionary paths. But don't expect just another preacher prophesying from the pulpit. This is more like peeling back layers of history, bit by bit. 28 Days of Spiritual Insights Each day within the book...

Continue Reading
Chemours Faces Legal Woes: Investor Actions by Dec. 7

Updated Category News Views 92

A Rough Road Ahead for Chemours Investors Well, folks, Chemours Company isn’t exactly living its best life right now. Following a tumble of 18.63% in its stock price after less-than-stellar second-quarter earnings, the legal hounds are circling the wagons. Investors who picked up shares between February 20, 2026, and August 4, 2026, might be feeling a bit sore right...

Continue Reading
Webull Faces Class Action Over Alleged Misleading Disclosures

Updated Category News Views 46

Webull's Disclosure Disaster: A New Chapter Unfolds This isn't just any ordinary day in the world of stocks—Webull Corporation (NASDAQ:BULL) is under the gun, facing a securities fraud class action lawsuit hotter than a frying pan. When lines blur between marketing bravado and operational reality, things tend to sizzle over—and that's exactly where Webull finds itself...

Continue Reading
New Paths Emerge in Thin Film Dewetting Control

Updated Category News Views 100

The Thin Film Challenge: Decoding Dewetting Ah, dewetting—it's a bit like trying to keep a chocolate bar solid on a scorching summer day. These thin films, they're supposed to hold their own, spread thin and steady. But apply a little heat or a laser, and watch them form tiny islands, like a retreating tide. Now, there's some fresh thinking in the air, straight from...

Continue Reading
Pampa Energía's Q3 2026: A Mixed Bag with Key Gains

Updated Category News Views 35

Scrutinizing Pampa Energía’s Performance in Q3 2026 Pampa Energía, that Argentinian energy powerhouse, is strutting its stuff with the latest financial results. But let's not jump on the bandwagon just yet. The numbers are a kaleidoscope, promising at first blush with a pang of caution underneath. Sales for Q3 2026 hit a robust US$790 million, a triumphant 34%...

Continue Reading
Atlas Power Expands with Boyland Electric Acquisition

Updated Category News Views 92

The Strategy Behind Atlas Power's Expansion Atlas Power Partners, no stranger to sizzling ambitions, has galvanized its portfolio by roping in Boyland Electric. This latest maneuver unfolds as Atlas hustles to become the go-to network for residential generator services. It’s a clear bet on 'quality over flair'—an ethos echoed by their CEO, David Fischer, who champions...

Continue Reading
Atlanta's Rental Dilemma: Supply High, Approvals Low

Updated Category News Views 88

Here's a head-scratcher for you: Atlanta just cranked out apartment buildings like they were goin' outta style, yet folks with cash in hand can't get a foot in the door. With a whopping 10.9% vacancy rate, you'd think they'd be rolling out the welcome mat. But oh no, what's actually playing gatekeeper is our ol' buddy, the credit score. Plenty of Apartments, Not Enough...

Continue Reading
3W Auto-life Unveils New Products at SEMA Show 2026

Updated Category News Views 80

Revving Up Interest at SEMA with 3W Auto-life If there's ever a mecca for car accessories in the automotive world, the SEMA Show in Las Vegas is it. Right there in the West Hall, Booth #54169, 3W Auto-life is flaunting their 2026 lineup, marking a decade of transformation in vehicle interior protection. From upgraded floor mats for the Tesla Model Y Juniper and the Toyota...

Continue Reading
Michael Schade Joins LIU as VP and General Counsel

Updated Category News Views 62

Shaping the Future with a Legal Vet Michael Schade slipping into the VP and General Counsel chair at Long Island University isn't just another nameplate shuffle. It's a solid move for a university looking to tighten its grip on being a major research player. A Power Player from the University of Oklahoma Schade isn't new to the world of academic law. He's packing legal...

Continue Reading

Top 5 Most Recently Viewed Articles

Netskope Demonstrates Impressive Q3 Growth Amid Industry Changes

Updated Category News Views 120

Netskope's Financial Performance Overview Netskope, a prominent player in cloud security and networking solutions, recently announced notable financial results for the third quarter of fiscal year 2026. With a focus on continuous innovation and market adaptation, the company achieved significant growth in several key metrics, reinforcing their position in the...

Continue Reading
Stack Capital Group Inc. Launches New Share Buyback Initiative

Updated Category News Views 76

Stack Capital Group Inc. Announces Normal Course Issuer Bid Stack Capital Group Inc. (TSX:STCK) has recently made waves with an announcement regarding a normal course issuer bid (NCIB) intended for its outstanding common shares. The management team has expressed strong confidence that the current share price does not accurately reflect the value of the company,...

Continue Reading
Parke Bancorp Declares Cash Dividend for Stockholders

Updated Category News Views 96

Parke Bancorp Announces Cash Dividend for Shareholders Parke Bancorp, Inc. (NASDAQ: PKBK) has made an exciting announcement regarding its financial performance and commitment to its investors. The company has declared a cash dividend of $0.18 per share. This positive development is intended to reward stockholders and reinforce Parke Bancorp's ongoing dedication to...

Continue Reading
Examining the Market Sentiment: Hancock Whitney's Position

Updated Category News Views 122

Understanding Hancock Whitney's Current Market Position Hancock Whitney Corporation (NYSE: HWC) has recently made headlines as its short percent of float has noticed a significant drop of 6.36%. This indicates a shift in trading trends for the company, with approximately 3.40 million shares being sold short, accounting for 5.45% of all available shares on the market. With...

Continue Reading
Unlocking Potential: Benefits of FansHash Cloud Mining

Updated Category News Views 139

Understanding XRP's Stellar Performance This year has been a remarkable journey for XRP, witnessing an impressive rise of over 100% as of mid-year. The currency has carved out its niche in cross-border payments and the decentralized finance (DeFi) sector. What sets XRP apart is its efficiency, with transaction settlement times of just 3-5 seconds and very low fees, making...

Continue Reading